21
Monday
September 2020
6:02 AM IST
News Headlines
Burkina Faso striker Traore leaves Lyon for Aston Villa        AIFF to conduct three-day International Virtual Conference for coaches        Looking to play good brand of cricket to make this season a memorable one: KL Rahul        US stocks fall as market decline extends for third week        No decision to discontinue printing of Rs 2000 note: FinMin        Iran vows 'hit' on all involved in US killing of top general        Russia's Navalny says he's now more than 'technically alive'        Pak uses drone to weapons in J-K's Rajouri; 3 LeT terrorists arrested        Centre rejects study which claims India is world's largest emitter of anthropogenic sulphur dioxide        Garib Kalyan Rojgar Abhiyaan not implemented in Bengal as state did not provide any info: FM        Parliament's monsoon session likely to be curtailed, may end by mid-next week        Kerala reports 4,000 plus fresh COVID-19 cases for second day in row; Toll crosses 500        China flies 18 warplanes near Taiwan during US envoy''s visit        US bans WeChat, TikTok citing national security        IPL 2020: Dhoni''s CSK lock horns with Rohit led MI in opener        US Open champion Osaka out of French Open due to injury        NIA questions Ker Minister Jaleel for over 8 hours; No need for him to resign, says CM        Delhi riots: Police files charge sheet under UAPA against 15 for larger conspiracy        Serum Institute gets DGCA''s nod to resume testing of Covid vaccine again        Russia''s RDIF collaborates with Dr Reddy''s Laboratories for Sputnik V vaccine trials, distribution: CEO        
Home   | Main News   | Kerala  | National   | International  | Business   | Sports   | Entertainment   | Columns   | Offbeat   | Health   | About Deepika 
National News
DCGI nod to Serum Inst. of India for phase 2 & 3 clinical trials of Oxford COVID-19 vaccine
 
New Delhi: The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India for conducting phase 2 and 3 human clinical trials of the Oxford University''s COVID-19 vaccine candidate in the country, according to the Health Ministry. Government officials told PTI that DCGI Dr V G Somani granted the approval late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on COVID-19. "The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said, referring to the Central Drugs Standard Control Organisation (CDSCO).

“As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said. The DCGI has given approval to SII, Pune, to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India and this will hasten the development of the COVID-19 vaccine, the health ministry said in a statement. As a rapid regulatory response, the expert panel at the CDSCO on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, ''Covishield'', on healthy adults in India, the officials also said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa. The officials also said the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information. The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore. "According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of ''Covishield'' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19, had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said. To introduce the vaccine, SII, the world''s largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca.


Pak uses drone to weapons in J-K's Rajouri; 3 LeT terrorists arrested
Centre rejects study which claims India is world's largest emitter of anthropogenic sulphur dioxide
Garib Kalyan Rojgar Abhiyaan not implemented in Bengal as state did not provide any info: FM
Delhi riots: Police files charge sheet under UAPA against 15 for larger conspiracy
Serum Institute gets DGCA''s nod to resume testing of Covid vaccine again
Russia''s RDIF collaborates with Dr Reddy''s Laboratories for Sputnik V vaccine trials, distribution: CEO
Would you have said same thing if it was Shweta or Abhishek in my place: Kangana to Jaya
NDA candidate Harivansh Narayan Singh re-elected as Rajya Sabha Deputy Chairman
''Busy with peacocks'', says Rahul in dig at PM over rise in COVID cases
Shah again in AIIMS
Kangana meets Maha Guv amid row with Sena, seeks ''justice''
Expect COVID-19 vaccine by early next year, will take first shot if any trust deficit: Vardhan
India, Russia collaborating on COVID-19 vaccine ''Sputnik V'', clinical trials likely this month
Efforts on for online delivery platform for street vendors: PM
Omar Abdullah to vacate govt accommodation in Srinagar
Maha Home Minister Anil Deshmukh again gets threat calls
Kangana to face ''drug link'' probe; Mumbai home under BMC lens
Deepak Kochhar arrested in ICICI Bank loan scam
Kangana 1st Bollywood star to be guarded by CRPF commandos
GST second major attack on India's unorganised economy: Rahul Gandhi
ENTERTAINMENT NEWS
My whole life has been a miracle: Rajinikanth
 Mumbai: From starting out as a bus conductor to becoming one of the biggest stars of the: country,  
'Game of Thrones' star Indira Varma tests positive for coronavirus
Coronavirus: Release of Ranveer Singh-starrer '83' put on hold
'Joker' earns Joaquin Phoenix his maiden Oscar
INTERNATIONAL NEWS
Iran vows 'hit' on all involved in US killing of top general
 Tehran, Sep 19 (AP) The chief of Iran's paramilitary Revolutionary Guard threatened on Saturday to g
Russia's Navalny says he's now more than 'technically alive'
China flies 18 warplanes near Taiwan during US envoy''s visit
US bans WeChat, TikTok citing national security
KERALA NEWS
Take steps to attach properties of pvt financial institution; HC to govt
 Kochi: The Kerala High Court on Wednesday directed the state government to take steps to attach the
Kerala logs single-day highest spike of 3,830 COVID-19 cases
Jaleel has committed no wrong, says Kerala CM
"My hands are clean, not accepted any gift or money" Minister
Untitled Page
Rashtra Deepika LTD
Copyright @ 2020 , Rashtra Deepika Ltd.